INVEGA 3 MG
PALIPERIDONE : 3 MG · DIN 02300273 · JANSSEN INC
Health Canada status: MARKETED
What is INVEGA?
INVEGA 3 MG contains PALIPERIDONE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02300273, held by JANSSEN INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Oct-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INVEGA used for?
Treatment of schizophrenia and related psychotic disorders.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02300273 |
|---|---|
| Brand name | INVEGA |
| Generic / active ingredient | PALIPERIDONE : 3 MG |
| Manufacturer | JANSSEN INC |
| Strength | 3 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AX13 PALIPERIDONE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Oct-2007 |
| Original market date | 2007-10-02 00:00:00 |
How is it administered?
Recommended: 6 mg once daily. Range: 3-12 mg/day. Swallow whole; do not chew, divide, or crush. Take preferably in the morning without regard to meals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (section 11 is in TOC but text ends at section 7).
How is it supplied?
Bottles of 30 tablets.
Contraindications
Hypersensitivity to paliperidone, risperidone, or any ingredient in the formulation.
Warnings and precautions
Increased mortality in elderly patients with dementia. Risk of QT prolongation, Neuroleptic Malignant Syndrome, tardive dyskinesia, hyperglycemia, and orthostatic hypotension.
What can be used instead?
Other Canadian products sharing ATC code N05AX13 PALIPERIDONE. 11 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INVEGA | 6 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02300281 |
| INVEGA | 9 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02300303 |
| INVEGA SUSTENNA | 100 MG / 1 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02354233 |
| INVEGA SUSTENNA | 150 MG / 1.5 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02354241 |
| INVEGA SUSTENNA | 50 MG / 0.5 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02354217 |
| INVEGA SUSTENNA | 75 MG / 0.75 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02354225 |
| INVEGA TRINZA | 175 MG / 0.875 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02455943 |
| INVEGA TRINZA | 263 MG / 1.315 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02455986 |
| INVEGA TRINZA | 350 MG / 1.75 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02455994 |
| INVEGA TRINZA | 525 MG / 2.625 ML | SUSPENSION (EXTENDED-RELEASE) | JANSSEN INC | MARKETED | DIN 02456001 |
Who else supplies PALIPERIDONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PALIPERIDONE appears in 330 registered pack listings across 13 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.